CG Oncology (CGON) Retained Earnings (2023 - 2026)

CG Oncology has reported Retained Earnings for 4 years, with the latest figure at -$439.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 73.98% year-over-year to -$439.2 million; the trailing twelve-month figure through Mar 2026 stood at -$439.2 million (down 73.98% YoY), and the FY2025 full-year result was -$379.0 million, down 73.86% from the prior year.
• Retained Earnings for Q1 2026 stood at -$439.2 million, down from -$379.0 million in the prior quarter.
• The five-year high for Retained Earnings was -$129.9 million in Q4 2023, with the low at -$439.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$254.9 million across 4 years, with a median of -$235.2 million in 2024.
• Annual changes were most pronounced in 2024 — Retained Earnings tumbled 67.75% — and 2025, when it tumbled 81.36%.
• CG Oncology's Retained Earnings stood at -$129.9 million in 2023, then sank by 67.75% to -$218.0 million in 2024, then sank by 73.86% to -$379.0 million in 2025, then declined by 15.89% to -$439.2 million in 2026.
• The last three Retained Earnings figures came in at -$439.2 million (Q1 2026), -$379.0 million (Q4 2025), and -$337.7 million (Q3 2025), per Business Quant data.